{"name":"Tranzyme, Inc.","slug":"tranzyme-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":609000,"revenueGrowth":357.9,"grossMargin":0,"rdSpend":16125000,"netIncome":-26895000,"cash":29639000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2016"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Ulimorelin Intravenously (IV)","genericName":"Ulimorelin Intravenously (IV)","slug":"ulimorelin-intravenously-iv","indication":"Symptomatic gastroesophageal reflux disease (GERD) in patients with type 1 diabetes mellitus","status":"phase_3"},{"name":"Ulimorelin Invtravenously (IV)","genericName":"Ulimorelin Invtravenously (IV)","slug":"ulimorelin-invtravenously-iv","indication":"Symptomatic gastroesophageal reflux disease (GERD) in patients with type 2 diabetes mellitus","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"TZP-101","genericName":"TZP-101","slug":"tzp-101","indication":"Gastroesophageal reflux disease (GERD)","status":"phase_3"}]}],"pipeline":[{"name":"TZP-101","genericName":"TZP-101","slug":"tzp-101","phase":"phase_3","mechanism":"TZP-101 is a prodrug that is converted into its active form, which is a potent inhibitor of gastric acid secretion.","indications":["Gastroesophageal reflux disease (GERD)"],"catalyst":""},{"name":"Ulimorelin Intravenously (IV)","genericName":"Ulimorelin Intravenously (IV)","slug":"ulimorelin-intravenously-iv","phase":"phase_3","mechanism":"Ulimorelin is a ghrelin receptor agonist that stimulates gastric emptying.","indications":["Symptomatic gastroesophageal reflux disease (GERD) in patients with type 1 diabetes mellitus","Symptomatic diabetic gastroparesis"],"catalyst":""},{"name":"Ulimorelin Invtravenously (IV)","genericName":"Ulimorelin Invtravenously (IV)","slug":"ulimorelin-invtravenously-iv","phase":"phase_3","mechanism":"Ulimorelin is a ghrelin receptor agonist that stimulates gastric emptying.","indications":["Symptomatic gastroesophageal reflux disease (GERD) in patients with type 2 diabetes mellitus"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxNRmdwYnB3S0JMZ2NzQ0lMREtrQWxOZGVwZFlxNlpkZTlsam1TMDJLMi1QRTlkQVdfTVZQTl9xYkFVU2VkaUZQanV1R1RuZE81Q3hPdzR3eXJoRFViTXlmOW54MDJoTTF4YVduLUItRWRocHJjZEU1V2lNeHNRd2ZvLWVrdw?oc=5","date":"2018-11-27","type":"pipeline","source":"citybuzz -","summary":"Altimmune Appoints Vipin K. Garg, Ph.D. CEO - citybuzz -","headline":"Altimmune Appoints Vipin K. Garg, Ph.D. CEO - citybuzz -","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxNV3JQUlA5SzMxaHhveWlBU2c1NF9KRWYwUzdBSUVBaFhOcjhXOFpEZ2hhWExnc2Z2dy1ybF92WHFiYXZKVU9aRmt1Y0VaUFVjWlEtaXpKUlZpekdtRmlJN19Sb3hkLUpkT2NibGUtWnFINXhyREZnVDdEUV9WTUVBOTZLdw?oc=5","date":"2015-07-21","type":"pipeline","source":"BioSpace","summary":"10 Biotech Firms Rapidly Expanding in North Carolina - BioSpace","headline":"10 Biotech Firms Rapidly Expanding in North Carolina","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPdWgyaDdfZzhnb242MzFXSkpXSEs4cnlvTVBpTDBiQzJMazFMcHlkZnJVWGxYa25qWUtHLW5fVzdwWFNZSjNnSTF5ZXBLWHRsUWduakg3S0JlQzNINmVaRkRtYXcwNHVyZzVKNXQ5MmV0RHd1U2ZIS091OXcyQ3VSX0Z2d0x6T2FCUHBfUG9BSFVTTXFi?oc=5","date":"2013-07-16","type":"deal","source":"Contract Pharma","summary":"Ocera Therapeutics Completes Tranzyme Merger - Contract Pharma","headline":"Ocera Therapeutics Completes Tranzyme Merger","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":3},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar","revenue":609000,"revenuePeriod":"2016-12-31","revenueHistory":[{"value":609000,"period":"2016-12-31"},{"value":133000,"period":"2015-12-31"},{"value":341000,"period":"2014-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":16125000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-26895000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":29639000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}